Market Intelligence, Emerging Myeloid Immunotherapy Programs, and High-Purity Reagents for SIRPB1 Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SIRPB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIRPB1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View SIRPB1 Products |
| Gene Delivery | SIRPB1 Full-Length Lentivirus Premade particles for stable cell line generation. Co-expression with TYROBP (DAP12) recommended for surface display and signaling competence. |
View SIRPB1 Products |
| Benchmark Ab | Anti-SIRPB1 Reference Antibody Recombinant human IgG1 positive control for binding and functional assay development. |
View SIRPB1 Products |
| Validator | SIRPB1 siRNA Set Sequence-verified knockdown validators for specificity control in reporter and phagocytosis assays. |
View SIRPB1 Products |
| Related Target: SIRPA | SIRPA (CD172a) Essential for SIRP-family counter-screening and CD47-pathway reference comparator. |
View SIRPA Products |
| Related Target: TYROBP | TYROBP (DAP12) Adaptor protein required for SIRPB1 surface expression and ITAM-mediated signaling. |
View TYROBP Products |
| Related Target: CSF1R | CSF1R Synergistic myeloid reprogramming partner; relevant for combination-therapy mechanism studies. |
View CSF1R Products |
| Related Target: CD47 | CD47 Primary ligand for SIRPA; negative control for SIRPB1-specific drug design. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIRPB1 Surface Expression Requires DAP12 Co-expression | Full-length lentiviral particles with optional TYROBP (DAP12) co-transduction to restore native conformational epitopes on reporter cells. |
| SIRP Family Homology & Off-Target Risk | Human SIRPA, SIRPB1, and SIRPG ortholog proteins available; strict sequence verification enables precise cross-reactivity panels. |
| Cross-Species Cyno/Mouse Evaluations | Human, Cynomolgus, and Mouse SIRPB1 ECD-Fc proteins supplied at >95% purity for species cross-reactivity ELISA/SPR. |
| Agonist Antibody Screening & Functional Validation | HEK293-expressed ECD proteins preserving native glycosylation to accurately present conformational epitopes for agonist screening. |
| Assay Specificity & False Positives | Validated siRNA included for knockdown confirmation in reporter and phagocytosis assays; endotoxin controlled to eliminate TLR artifacts. |
Live SIRPB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SIRPB1 axis represents an emerging frontier in myeloid-targeted immunotherapy. While the CD47/SIRPA pathway has matured into a highly competitive clinical arena, it suffers from hematologic toxicities (e.g., anemia, thrombocytopenia) due to ubiquitous CD47 expression on red blood cells—the "antigen sink" effect. SIRPB1 offers a differentiated activating mechanism through DAP12 coupling and does not bind CD47, thus bypassing these safety liabilities. The current landscape is dominated by preclinical antibody and bispecific engineering programs seeking to unlock macrophage and NK-cell cytotoxicity without the toxicity profile of CD47 blockade. As first-generation SIRPα inhibitors face clinical hurdles, the industry is pivoting toward SIRPB1 as a myeloid-specific activator. Major players are advancing monoclonal antibodies and bispecific formats that selectively engage SIRPB1 while sparing the inhibitory SIRPα pathway. The next wave of R&D is targeting combination regimens with CSF1R inhibitors, PD-1/PD-L1 checkpoint blockade, and tumor-targeting bispecific formats to maximize myeloid effector recruitment and repolarize tumor-associated macrophages.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist Monoclonal Antibody | Preclinical biotech & academic translational centers; Emerging Biotech | Solid Tumors (TAM-rich), AML | Receptor clustering / DAP12 recruitment (Need full-length lentivirus stable cells for reporter assays) |
| Bispecific / Macrophage Engager | Immuno-oncology innovators; Oncology-Focused Biotech | Immune-excluded solid tumors, Colorectal, Lung Cancer | Heterodimer validation with tumor antigen (Need cross-reactive Ab controls and dual-target binding matrices) |
| Antagonist / Modulator | Autoimmune discovery programs | Chronic inflammation, RA, IBD | DAP12 signaling inhibition (Need cell-based calcium-flux and cytokine-release assays with SIRPB1/DAP12 co-expressing lines) |
| ADC | Myeloid-Targeted Programs | Acute Myeloid Leukemia | Internalization assay (Need high-purity ECD-Fc for binding validation and pH-dependent screening) |
| Cell Therapy (CAR-M) | Engineered Macrophage Programs | Solid Tumor Microenvironment | Transduction verification (Need reliable Lentivirus constructs for SIRPB1 domain engineering) |